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Clostridium difficile (C.difficile) is a pathogen of rapidly increasing public health importance. In 2013, the Centers for Disease Control and Prevention (CDC) labeled it as one of three -urgent threat‖ pathogens. This is the highest level possible, given to species that are -an immediate public health threat that requires urgent and aggressive action [1] . Subsequent recurrence of infection is dangerous and common for patients with C.
difficile. Recent studies show that 25-30% of patients with an episode of CDI will experience recurrence [4-6]. The rates are even higher in adults over 65 years, who remain symptomatic with diarrhea for longer than younger patients, and suffer greater debility following a CDI episode [7, 8] . Preventing CDI recurrence is essential, however, current strategies to hasten recovery and reduce recurrence are limited.
The most commonly prescribed method to treat CDI involves systemic antibiotic therapy with oral vancomycin or metronidazole [9] . During the past decade, success with these treatments has ranged from 64%-82% [10] . However, oral antibiotic therapy carries the risk of promoting antibiotic-resistant organisms or increasing relapse rates by further disrupting the microbiome. Older adults are at elevated risk for medication intolerance or side
effects [11] . Furthermore, oral vancomycin, increasingly the medication of choice for moderately severe CDI, is extremely expensive [12] . A newer antibiotic, fidaxomicin has a success rate similar to vancomycin, but is even more costly [13] . For alternative treatments, a single study of monoclonal antibodies has showed promising results [14] . However, their use in clinical care is limited based on their expense, their injectable form, and the fact that they are not commercially available. Probiotics represent a potentially promising approach to preventing recurrent CDI, by enhancing gut-associated immunity and ameliorating the gut microbiota imbalance that is a hallmark of CDI [15] . We hypothesize that probiotics, in conjunction with standard antibiotic therapy, will reduce the duration of diarrhea, reduce recurrence, and improve functional status in adults with initial episode of CDI. If probiotics are found to reduce recurrence, patients will experience fewer subsequent CDIs. Since antibiotics are standard therapy for CDI treatment, reducing the rate of future CDIs could greatly curtail the use of conventional antibiotics among these patients, thus providing substantial individual and societal benefit.
We will conduct a pilot randomized, double-blinded, placebo-controlled, phase two clinical trial in patients with a first episode of CDI, primarily to evaluate the efficacy of probiotic treatment for reducing the duration of diarrhea and CDI recurrence. We evaluate the effect that the probiotic use has in reducing the density of C. difficile toxin in stool, stool cytokines, and fecal lactoferrin, as well as its role in improving the functional ability of recovering patients. Given its rapidly increasing prevalence, addressing CDI could have profound physical and functional benefits.
This is a pilot randomized, double blinded, placebo controlled, phase two clinical trial in adult patients with a first episode of CDI. It is designed to test the hypothesis that compared to standard care and placebo, daily oral probiotic as adjunctive treatment for CDI will reduce the duration of diarrhea and the incidence of CDI recurrence. Both the experimental and control groups receive antibiotics for treatment of CDI as outlined in recent multinational guidelines for management of CDI [16, 17] . Enrollment in the trial is from February 2013 to February
2015.
Probiotics have several effects which may promote improved immune system functioning. These include modulating the gut microbiota and interacting with the innate and adaptive immune systems of the host [18] [19] [20] [21] . At the level of the intestinal epithelium, probiotic strains also preserve or strengthen the mucosal gastrointestinal barrier by prevention of bacterial adherence to the epithelial lining. This occurs through competitive exclusion, inhibition of pathogenic induced alterations of epithelial permeability, and regulation of enterocyte gene expression involved in maintenance of the mucosal barrier.
We are using a combination probiotic of 4 bacterial strains as the intervention in our study. Human studies confirm the immunostimulatory effects of the probiotics to be used in this study. shown to significantly increase serum immunoglobulin G levels [22] . A probiotic combination in which Lactobacillus paracasei (L. paracasei) Lpc-37 was the main component has been
shown to significantly increase phagocytic activity of monocytes and granulocytes in healthy subjects [23] . Finally, L. acidophilus NCFM ® has been shown to reduce cold and flu duration in children [24] , alter allergic rhinitis-associated biomarkers [24] , and enhance cellular immunity in older adults [25] .
Survival during passage through the host gastrointestinal tract, including acidic and alkaline environments, is essential for the successful activity of probiotics. All four probiotic strains used in this study are able to survive acidic concentrations equivalent to those of the stomach, and concentrations of bile salts equivalent to those of the duodenum. Additionally, L. The inclusion and exclusion criteria for subject enrollment are summarized in Figure 1 . , elevated creatinine > 1.5 times the premorbid level, or toxic megacolon [28, 29] . Other exclusion criteria include prior history of CDI, another known etiology of diarrhea (e.g., other enteric pathogen, other intestinal disease), a history of chronic intestinal disease (e.g., Crohn's disease, ulcerative colitis), the presence of ileus, colostomy, gastric tube, or naso-gastric tube, and a history of abdominal surgery within the 3 months prior to study enrollment. Patients are also excluded if they are currently enrolled in another investigational drug trial,
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unavailable for follow-up visits, or not willing to stop using other probiotics for the duration of the study. In addition, patients are excluded if they are severely immunocompromised, as defined by either having the diagnosis of HIV, AIDS, or a primary immunodeficiency, or having a very recent solid organ or bone marrow transplant.
Although probiotics have been used safely in studies with pregnant women, known pregnancy is another exclusionary criterion for enrollment in our study. We do not require a pregnancy test before study enrollment, however if a woman determines that she is pregnant during the study period, she must stop the study medication. She will continue other procedures as listed in the protocol. Two $50 checks are provided as study compensation, for a total compensation of $100. One check is given for the completion of Study Visit 1 (Week 0) and the second check for completion of Study Visit 3 (Week 8) at the end of study. A subject has to complete all three study visits to receive the entire amount.
Our trial is double blinded, using an identical matching placebo. Both the subjects and research team are blinded. For the study investigators to remain blinded, assignment to study intervention or placebo takes place centrally at the University of Wisconsin research pharmacy using a random-number generator. The research pharmacy has no stake in studies, and specializes in systems to promote allocation concealment. Treatment allocation is by random assignment in a 1:1 ratio in permuted blocks of 4. Since other studies have found that the recurrence rate is similar with vancomycin and metronidazole and the severity of illness is not closely related to recurrence, we have not stratified by these additional factors [30] . The unit of randomization is the individual.
The intervention is the administration of a probiotic combination. The subject takes the oral probiotic or placebo every day for 28 days. After week four, the subjects ceases taking
the probiotic or placebo. All subjects are followed for CDI recurrence until week eight. All also Placebo: The placebo is identical to the study treatment in appearance and taste, and contains the inert filler that the active product also contains. The manufacturer, Danisco, supplies the placebo. The placebo is also administered in addition to a standard duration course of standard antimicrobial therapy for a first episode of CDI.
A study diagram is shown in Figure 2 , and intervention details are outlined below.
Week 0: Recruit, consent, enroll, randomize. Week 0-4: Intervention. Week 4-8: Washout, monitor recurrence.
Study Visit 1:
At the first visit, week zero, the subject is enrolled following informed consent, and randomized to probiotic or placebo. An initial stool sample is collected. During hospitalization, subjects are followed daily for diarrhea history, record of concomitant medications, adverse effects, and their response to treatment using a stool diary.
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Upon discharge, subjects are followed through weekly clinic visits or telephone calls to identify continuing symptoms of CDI, side effects from the medication, and any problems taking the medication. Functional status is assessed by the Barthel Index [31] . All subjects are given a stool diary card to report diarrhea history. A modified version of the Bristol stool consistency scale is used for the assessment of diarrhea [32] . The subjects fill out the stool diary daily for 8 weeks, beginning at enrollment.
Home collection kits are also given at visit 1, and subjects are trained in stool collection. Subjects are asked to bring their stool samples to visits 2 and 3. Sample collection is allowed within 4 days of the expected date, to coincide with clinic visits. Stool samples are collected in a sterile container, and brought or mailed to the clinic.
Study Visit 2:
After 28 days, the subject stops taking the probiotic or placebo. A stool sample is collected, and the stool diary is reviewed for diarrhea duration and CDI recurrence.
Study Visit 3:
At week 8, a final stool sample is collected, and the stool diary is reviewed for CDI recurrence.
If subjects have signs or symptoms of recurrent CDI at any point during the study after resolution of the initial episode, an additional stool sample is collected. If a subject is diagnosed with recurrent CDI, they will be discontinued from study treatment and treated according to standard of care for recurrent CDI.
We measure medication adherence using the Medication Event Monitoring Systems (AARDEX Ltd, Switzerland) cap data, pill counts at the week 4 visit, and self-reporting at weekly phone calls. Tolerability is an important factor in subject adherence to a potentially beneficial intervention. The four strains proposed for this study have all demonstrated good
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tolerability in human subjects.
All subjects are informed during enrollment that they may discontinue participation at any time. We ask that they contact the study coordinator if they decide to drop-out of the study. If the subject is willing, the research coordinator arranges a research clinic visit to collect a final stool sample and stool diary charts. Intention to treat analysis will be performed on all patients lost to follow up.
We hypothesize that modulation of the gastrointestinal flora and enhancement of systemic immune functioning by a probiotic combination consisting of equal amounts of L.
acidophilus NCFM ® , B. lactis Bl-04, B. lactis Bi-07, and L. paracasei Lpc-37 will lead to a twoday reduction in the duration of diarrhea, and a reduction in CDI recurrence, as compared to placebo and standard care. The beneficial effects may be mediated by competitive exclusion (gastrointestinal colonization) and immunostimulation (nasal colonization). While we are not studying all the potential mechanisms of probiotics, the two we have chosen to include are the most biologically plausible and the most relevant to C. difficile infection.
We define diarrhea as the presence of three or more loose stools in a 24 hour period [33] . Stool diaries are collected daily from baseline for 8 weeks. We define -loose stools‖ as levels 1-4 on our in-house stool scale, as self-recorded in subject's diary. This visual stool scale is provided to all patients at enrollment, and available from the corresponding author upon request. Levels 1-4 correspond to Bristol stool levels 5-7 [32] . All subjects will be evaluated for duration of diarrhea: the time period between when diarrhea started, and when
less than 3 loose stools are reported in the stool diary. We hypothesize that the group treated with probiotics will have a two-day reduction in the duration of diarrhea, compared to the placebo group.
CDI recurrence is evaluated for all patients who re-experience symptoms after successful treatment of their initial CDI. Recurrence is defined as the presence of C. difficile toxin in the stool, after successful treatment of an initial CDI. The presence of C. difficile toxin is assessed by an enzyme immunoassay, as discussed in microbiologic analysis section below. Recurrence can take two forms, relapse of the initial infection and reinfection by a new strain. Relapse and reinfection is distinguished by analyzing C. difficile toxin in a stool sample submitted during the second symptomatic period. For relapse, subjects having a stool isolate identical to stool isolate(s) from the original infection is assessed by genotyping via Pulse
Field Gel Electrophoresis. The episode is considered reinfection if the strains of CDI are found to not be related. Given previous studies in the literature, we anticipate that relapse will be more common than reinfection [34] .
As secondary outcomes, we hypothesize that compared to placebo, probiotic treatment will significantly decrease the density of C. difficile toxin in the stool, fecal cytokines, and fecal lactoferrin, and improve the functional ability of recovering patients. Measurement of these outcomes are described below.
Isolation of fecal anaerobic bacteria:
We hypothesize that the competitive exclusion of pathogens in the gastrointestinal tract occurs by an increase in normal fecal microbiota. With the probiotic, we expect to see increases in fecal lactic acid bacteria compared with subjects receiving placebo. Probiotics may also have effects on the non-lactic acid bacteria of the gut,
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and thus stool processing for major categories of anaerobes is being undertaken using microbiome analysis. We expect that in the group receiving probiotics, there will be a greater preponderance of the lactobacilli compared with placebo.
Assessment of probiotic presence in fecal samples: 0.1 grams of fresh stool is added to 0.9 mL of sterile phosphate buffered saline (PBS) and diluted to 10 
C. difficile toxin, lactoferrin and cytokines:
A stool sample is collected on all subjects at baseline, 4 weeks, and 8 weeks, to determine the presence of C. difficile in qualitative stool cultures, using broth enrichment followed by culture on Clostridium difficile Brucella Agar.
Toxin quantitation is done using an ELISA methodology (tgcBIOMICS). 
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causing bacteremia and transferring antibiotic-resistant genes. In a 10-year survey conducted in Finland, no incidents of bacteremia due to L. acidophilus NCFM ® were found [35] . Clinical infections, including bacteremias, due to Lactobacillus species most often arise from the patient's endogenous microbiota. The majority of clinical infections due to lactobacilli species from probiotics occur in immunocompromised or severely ill patients, which we have excluded in our study. Finally, genomic analysis has found none of the genetic elements known to be associated with transfer of antibiotic resistance to be present in L. acidophilus NCFM ® [36] .
Bifidobacterium species have long been considered safe for human consumption, and their safety has been studied in many publications [37, 38] . If an adverse or severely adverse event occurs, timely, accurate and complete reporting and analysis of safety information will be undertaken. The following events will be reported as serious adverse events: An increase from normal laboratory values at baseline to the modified National Cancer Institutes criteria of Grade 3 or more, an increase of laboratory values from modified National Cancer Institutes criteria grade 1 or 2 at baseline to grade 4, a new cancer diagnosis, and medical events of interest [39] .
Research data is handled with utmost confidentiality and discretion. Subjects are assigned a unique identification number that can be traced only by the research specialist and PI. The file linking study identification numbers to identifiable information is stored and secured separately from the coded data. All subject information is kept in locked drawers, file cabinets or secure computer files, with access only allowed to research personnel. The final trial dataset will be available to all research personnel.
Data safety monitoring is performed by an independent Data Monitoring Committee (DMC) of the University of Wisconsin at Madison Institute for Clinical and Translational
Research. The DMC ensures subject safety, research data integrity, and compliance with federal regulations in the proposed research. The DMC also preforms periodic auditing of trial conduct, and makes recommendations that could include actions of continuation, modification, or termination.
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Sample size justification: We are conducting a randomized controlled trial with probiotic and placebo randomized in a 1:1 manner. This is a pilot feasibility study. We hypothesize that probiotic therapy will reduce the mean duration of diarrhea by two days. Estimates from the literature would suggest that in our elderly population the average duration of diarrhea is 10.2 days with a standard deviation of 2.32 days when treated with the standard antibiotic regimen [40, 41] . Using a two-sided nonparametric Wilcoxon rank-sum test with a 0.05 significance level, an N of 23 subjects per group is needed to achieve 80% power to be able to detect a reduction of 2 days. Adjusting for a 20% drop out rate increases the final sample size to a total of 58 subjects, 29 in each arm. Therefore, the target population will be 58 adults aged 18 years or older, over a period of two years. Because this is a pilot feasibility study, a sample size calculation for the second primary end point recurrence was not conducted.
Data analysis:
Following descriptive statistical analyses, and assessment of missing data, intention to treat analysis will be used. Duration of diarrhea will be compared between treatment and control groups using a Wilcoxon rank-sum test, and analysis of covariance will be used to adjust for gender and other relevant covariates. Chi-square test will be used to compare the recurrent CDI rate between treatment and control groups, and logistic regression will be used to adjust for gender and other relevant covariates. Density of C. difficile toxin, fecal cytokines and lactoferrin will be compared using Wilcoxon rank-sum test, using log transformation if necessary, and analysis of covariance will be used to adjust for covariates as necessary. Analysis of fecal cytokines is exploratory and levels will be compared among treatment groups using Wilcoxon rank-sum test. The Barthel index is exploratory and scores will be compared within and between subjects.
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This study will identify the major mechanisms by which probiotics are expected to mediate their effect on CDI symptoms and recurrence. In turn, shortened duration of CDI and decreased recurrence will help to reduce the disease burden of C. difficile. Probiotics offer the potential for safe, low cost, non-antibiotic adjunct therapy to standard treatment regimens. By studying probiotics in a population that includes older adults, we hope to shed new light on the treatment of C. difficile in a high-risk population, in which CDIs are disproportionately fatal.
The primary limitation of this study is the sample size. This was designed as a pilot study, and the recruitment goal over a two year period is 58 patients with mild to moderate C.
difficile. This trial is planned to assess feasibility, attrition,completion of study procedures, and recruitment challenges, prior to undertaking a larger study.
Because this study is being conducted at a single site, recruitment is particularly vulnerable to changes in local CDI patterns. The study site is working diligently to decrease rates of hospital acquired CDI. If these infection prevention efforts are successful, or the enrollment rate for eligible subjects is less than anticipated, it may be difficult to meet our recruitment goal during the two year period. Furthermore, limiting the study to non-severely immunocompromised, non-ICU patients without a prior history of CDI, excludes high CDI risk populations, and is another potential recruitment challenge.
Finally, by excluding subjects with severe CDIs, we are unable to investigate the role of probiotics for preventing C. difficile recurrence in these patients. Patients affected by severe CDIs are at a higher risk for clinical complications, often have longer recovery times, and may require more aggressive therapy. People with severe CDI would benefit greatly from a reduction in the rates of CDI recurrence, and it is important to include these patients in future studies.
